Key Highlights
● InfuSystem posted Q2 2026 net Revenue of $36.9 million, up 2.6% year-over-year.
● Gross Margin widened to 58.0% from 55.2%, with Adjusted EBITDA reaching a 23.4% margin.
● Two analysts carry Buy ratings, with price targets of $20 and $15 respectively.
● Management reaffirmed full-year guidance of 6% to 8% pro forma revenue growth.
InfuSystem Holdings, Inc. (NYSE American:INFU) reported record quarterly revenue in early August, and the market commentary that followed has centred on how Wall Street views the medical device services provider. The company, which supplies infusion pumps and related services to oncology, wound care and other clinics, reaffirmed its 2026 outlook alongside the results. With a small group of analysts publishing targets well above recent trading levels, investors may be weighing whether execution can keep pace with those expectations. No major US index membership could be verified for the stock from available sources.
Latest Company Context
For the second quarter ended June 30, 2026, InfuSystem posted net revenue of $36.9 million, up 2.6% from $36.0 million a year earlier. Excluding the restructuring of a contract with GE Healthcare, pro forma growth was 7.5%. Gross margin widened to 58.0% from 55.2%, Net Income rose to $3.2 million, or $0.15 per diluted share, and Adjusted EBITDA reached $8.6 million, a 23.4% margin. Management reaffirmed full-year guidance of 6% to 8% pro forma net revenue growth and an Adjusted EBITDA margin in the mid-to-low 20% range. Chief Executive Carrie Lachance described the period as another strong quarter. These figures are preliminary until the Form 10-Q is filed. Six-month net revenue was $70.6 million, little changed from $70.7 million a year earlier, and Operating Cash Flow over that period was $7.7 million.
Key Business and Index Drivers
The mix underneath the headline is shifting. Patient Services revenue rose 15.2% to $24.8 million, with oncology passing $20 million in quarterly revenue for the first time and wound care growing roughly 154% on new compression therapy products. Device Solutions fell 16.1% to $12.1 million, reflecting the GE Healthcare restructuring and a prior-year equipment rental buyout. The Balance Sheet remains modest in leverage: total Debt was $20.4 million, net debt $19.5 million, and the ratio of net debt to trailing Adjusted EBITDA was 0.61 times. The company repurchased $3.5 million of stock in the quarter. On the analyst side, two covering analysts each carry a Buy rating. B. Riley raised its target to $20 on August 5, while Roth Capital's target stood at $15 from February. Those are third-party opinions, not forecasts the company endorses.
What Investors Should Watch
Investors may watch whether third-quarter results show the pro forma growth rate tracking toward the 6% to 8% guidance range, given that first-half reported revenue was essentially flat at $70.6 million. The pace of the Device Solutions decline, and how much of the GE Healthcare effect, about $7.1 million for the full year, is already in the base, could shape comparisons. Operating cash flow for six months fell 12% to $7.7 million, so cash conversion and net debt, which rose from $16.4 million at year-end, are also worth monitoring. Further wound care traction and any change to analyst targets after the next report could influence sentiment. Thin analyst coverage may mean estimate revisions have an outsized effect on how the shares are perceived. Quarterly commentary from management on cadence, and any update to the Form 10-Q, could also help clarify the trajectory.
A Margin Story Still Waiting on Growth to Catch Up
InfuSystem enters the autumn with improving margins, a clean balance sheet and reaffirmed guidance, set against a small analyst pool whose targets imply meaningful upside that may or may not be realised. The case rests on converting patient services momentum into steady consolidated growth as the GE Healthcare headwind laps.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...